Skip to content

Cognitive Protection - Dexmedetomidine and Cognitive Reserve

Cognitive Protection - Dexmedetomidine and Cognitive Reserve

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00455143
Enrollment
27
Registered
2007-04-03
Start date
2006-09-30
Completion date
2009-04-30
Last updated
2019-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PD, POCD, Postoperative Cognitive Dysfunction, Postoperative Delirium

Keywords

Postoperative delirium, PD, Postoperative cognitive dysfunction, POCD

Brief summary

This is a pilot study to evaluate the effect of dexmedetomidine in the prevention of delirium in non-cardiac surgical patients. The preliminary data regarding the effect of dexmedetomidine on delirium comes from a study underway at Stanford. We propose to randomize fifty patients into two different protocols, one using dexmedetomidine until PACU discharge (hip replacement) and the other using dexmedetomidine for 24 hours in a monitored setting.

Detailed description

Elderly patients who undergo anesthesia and non-cardiac surgery are subject to deterioration of brain function including the development of postoperative delirium (PD) and postoperative cognitive dysfunction (POCD). These disorders cause disability, distress for both patients and their families, are associated with other medical complications and account for significant additional health care costs. We currently use relatively primitive approaches to preventing and treating PD and POCD. The proposed is a pilot study for an NIH grant which was recently submitted. This is a randomized controlled trial of perioperative dexmedetomidine to prevent PD and, potentially, POCD. Fifty patients will be enrolled at Mount Sinai with two different surgeries, either hip replacement or vascular bypass. The patients undergoing hip replacement will receive dexmedetomidine until discharge from the PACU. Vascular surgery patients who are transferred from the PACU to a monitored step-sown unit will continue dexmedetomidine for 24 hours.Participants will be screened for Mild Cognitive Impairment (MCI), and undergo preoperative cognitive testing. Unlike the parent trial, we will test for but will not select for patients with MCI. Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Follow up studies will include surveillance for delirium while in the hospital and cognitive testing at 3 months following surgery. Dexmedetomidine is a drug used for sedation in critically ill patients that provides some pain relief and controls the bodies response to stress. The sedation produced by dexmedetomidine appears more similar to natural sleep than any other drug used for anesthesia and postoperative sedation. Data suggesting that dexmedetomidine can prevent delirium following cardiac surgery and the developing understanding of the causes of PD and POCD suggest that dexmedetomidine will be particularly effective.

Interventions

Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.

DRUGPlacebo

Matching placebo given prior to surgery and continued for 24 hours postoperatively

Sponsors

Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age 65 years and older * elective major hip replacement or peripheral vascular (major surgery is defined by a planned 2 day hospitalization) * ASA physical status I-III * capable and willing to consent

Exclusion criteria

* Cardiac surgery * Intracranial Surgery * Emergency Surgery * Patients with severe visual or auditory disorder/handicaps * Illiteracy * Patients with clinically significant Parkinson's Disease * Patients not expected to be able to complete the 3 month postoperative test * Sick sinus syndrome without pacemaker * Hypersensitivity to drug or class * Current 2nd or 3rd degree AV block * History of clinically significant bradycardia * Contraindication to the use of an 2A-agonist * Presence of a major psychiatric condition such as bipolar disorder, major depression, schizophrenia, or dementia * ASA physical status IV or V

Design outcomes

Primary

MeasureTime frame
Functional Recovery3 months post surgery

Secondary

MeasureTime frame
Cognitive Testingprior to surgery
Delirium Assessmentsprior to surgery

Countries

United States

Participant flow

Recruitment details

Recruitment period from September 2006 to March 2008

Participants by arm

ArmCount
All Participants
All participants enrolled in study. Study never unblinded. Information not available by arms.
20
Total20

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyNo longer met Inclusion Criteria1
Overall StudyPhysician Decision1
Overall StudyStaff was not avail to follow patient2
Overall StudySurgical time, staff not available1
Overall StudyWithdrawal by Subject1

Baseline characteristics

CharacteristicAll Participants
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
20 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Sex: Female, Male
Female
14 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 24
other
Total, other adverse events
6 / 24
serious
Total, serious adverse events
0 / 24

Outcome results

Primary

Functional Recovery

Time frame: 3 months post surgery

Population: Main protocol became funded, study terminated, data not collected.

Primary

Functional Recovery

Time frame: 6 months post surgery

Population: This study terminated because main study became funded, data not collected.

Secondary

Cognitive Testing

Time frame: prior to surgery

Population: This study terminated because main study became funded, data not collected.

Secondary

Cognitive Testing

Time frame: 3 months post surgery

Population: Main protocol became funded, study terminated, data not collected.

Secondary

Cognitive Testing

Time frame: 6 months post surgery

Population: Main protocol became funded, study terminated, data not collected.

Secondary

Delirium Assessments

Time frame: prior to surgery

Population: Main protocol became funded, study terminated, data not collected.

Secondary

Delirium Assessments

Time frame: duration of PACU stay, up to 4 days post-op

Population: Main protocol became funded, study terminated, data not collected.

Secondary

Delirium Assessments

Time frame: 3 months post surgery

Population: Main protocol became funded, study terminated, data not collected.

Secondary

Delirium Assessments

Time frame: 6 months post surgery

Population: Main protocol became funded, study terminated, data not collected.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026